Trust Signals
- Written by the FormBlends Medical Team, reviewed against FDA approval records, phase 3 trial publications, and WADA prohibited list documentation.
- Every confidence rating in the evidence ledger is assigned independently of commercial interest.
- No affiliate links to peptide vendors. No sponsored claims.
- Page updated 2026-05-29. Regulatory status reflects FDA and EMA records as of that date.
Key Takeaways
- MT1 (afamelanotide) is a 13-amino-acid alpha-MSH analog approved by the FDA in 2019 at a 16 mg implant dose for erythropoietic protoporphyria. MT2 has no approved indication.
- MT2 binds four melanocortin receptors (MC1R, MC3R, MC4R, MC5R) versus MT1's primary MC1R selectivity, which explains MT2's erection, nausea, and appetite side effects.
- Bremelanotide (PT-141), an MT2 metabolite, is itself FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder, confirming the MC4R pathway is pharmacologically real.
- Lyophilized peptide purity should be confirmed by HPLC above 98 percent and mass spectrometry; a COA citing purity without an HPLC trace is insufficient for any injectable.
- MT2 is listed on the WADA Prohibited List under peptide hormones and related substances; MT1 outside its EPP medical indication is similarly scrutinized in competitive sport.
Direct Answer: MT1 vs MT2 Peptide in Plain Terms
MT1 (afamelanotide) and MT2 (melanotan II) are both synthetic melanocortin peptides that darken skin by stimulating melanin production, but they are not interchangeable. MT1 is FDA-approved, MC1R-selective, and carries a well-characterized safety profile at its clinical dose. MT2 is unapproved, binds four receptors, and produces a broader and less predictable set of systemic effects including spontaneous erections, nausea, and appetite suppression.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How do MT1 and MT2 differ in structure?
- What receptors do they bind and what do those numbers mean?
- Evidence ledger: what does the science actually support?
- Which peptide produces a stronger tan?
- What are the real side effects of each?
- Honest head-to-head comparison table
- What most pages get wrong about MT1 vs MT2
- Why the storage and stability rules exist: the chemistry
- How to read a COA and judge a peptide product
- FAQ
- Sources
How Do MT1 and MT2 Differ in Structure?
Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid endogenous peptide. Both MT1 and MT2 are synthetic analogs engineered for longer half-life and greater receptor affinity than natural alpha-MSH, which has a plasma half-life of only a few minutes.
MT1 (afamelanotide): A 13-amino-acid linear peptide. The key modification is substitution of a norleucine residue at position 4 (replacing methionine) and a D-phenylalanine at position 7. These changes increase metabolic stability and MC1R binding affinity relative to native alpha-MSH. Molecular weight approximately 1646.9 Da.
MT2 (melanotan II): A shortened, cyclic 7-amino-acid peptide. Cyclization via an amide bridge between aspartic acid and lysine residues constrains the backbone into a conformation that gains MC4R and MC3R access not available to the linear structure of MT1. Molecular weight approximately 1024.2 Da.
The cyclic backbone is the single structural decision that explains almost every pharmacological difference between the two compounds.
What Receptors Do They Bind and What Do Those Numbers Mean?
The melanocortin receptor family has five members (MC1R through MC5R). Their tissue distribution determines what happens when each is activated.
| Receptor | Primary tissue | MT1 affinity | MT2 affinity | Functional result of activation |
|---|---|---|---|---|
| MC1R | Melanocytes, skin | High (low nM Ki) | High | Eumelanin synthesis, tanning |
| MC3R | Brain, gut, adipose | Minimal | Moderate | Energy homeostasis, appetite |
| MC4R | Hypothalamus, spinal cord | Very low | High | Erections, appetite suppression, autonomic effects |
| MC5R | Exocrine glands, immune cells | Very low | Moderate | Exocrine secretion, immune modulation |
The Ki values for afamelanotide at MC1R have been reported in the low nanomolar range in binding studies published by Clinuvel (the developer) and in academic melanocortin pharmacology literature. Melanotan II's MC4R affinity is in a similar low-to-mid nanomolar range, which is why its CNS effects are robust even at doses in the low microgram-per-kilogram range.
Evidence Ledger: What Does the Science Actually Support?
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| MT1 reduces phototoxic reactions in EPP patients | Human RCT (Langendonk et al., NEJM 2015, n=93) | Positive, significant | High |
| MT1 increases skin melanin in fair-skinned individuals | Human RCT (phase 2 and phase 3 Clinuvel trials) | Positive | High |
| MT2 causes spontaneous erections | Human phase 1/2 studies (Wessells et al., JURO 1998, n=10) | Positive | Moderate |
| MT2 produces skin tanning | Small human studies, case series | Positive | Moderate (small samples) |
| MT2 suppresses appetite / reduces body weight | Animal (rodent) studies; limited human data | Positive in animals | Low (no robust human RCT) |
| MT2 causes nausea and flushing | Human phase 1/2 reports, case literature | Adverse, consistent | High |
| Bremelanotide (MT2 metabolite) treats HSDD in women | Human RCT (RECONNECT trials, FDA NDA 210557) | Positive | High |
| MT2 raises blood pressure transiently | Human phase 1 data, bremelanotide prescribing info | Adverse signal | Moderate |
| MT1 prevents melanoma or other skin cancers | No human trial; theoretical from melanin biology | Unproven | Very low (speculation) |
Which Peptide Produces a Stronger Tan?
No published head-to-head randomized trial has compared MT1 and MT2 directly for tanning magnitude in healthy volunteers. What the evidence shows separately:
- MT1 at 16 mg (implant) over a 60-day period produces measurable increases in melanin density in EPP patients, documented by reflectance spectroscopy in the NEJM 2015 trial by Langendonk and colleagues.
- MT2 at doses ranging from roughly 0.025 to 0.1 mg/kg subcutaneously produced erythema and tanning responses in the early Wessells and Hadley studies, though sample sizes were very small (fewer than 15 subjects in most reports).
- Anecdotal community reports consistently describe MT2 as producing faster visible tanning, possibly because MC4R or MC3R co-stimulation amplifies the melanocyte response or because users administer higher effective MC1R-equivalent doses.
Conclusion: MT1 has robust evidence for clinically meaningful tanning at its approved dose. MT2's tanning evidence is real but thin. Neither compound's cosmetic tanning efficacy has been tested in a properly powered RCT against placebo in healthy adults.
What Are the Real Side Effects of Each?
MT1 (afamelanotide, Scenesse): The FDA label and phase 3 trial data identify implant-site reactions (pain, bruising, induration) as the most common adverse events. Nausea and headache occurred in a minority of subjects. No cardiovascular signal was identified in the EPP program. Hyperpigmentation of existing nevi is a recognized finding.
MT2: Side effects are more varied because of multi-receptor activity. The early human studies and subsequent case literature report:
- Nausea, often within 30 to 60 minutes of injection, affecting a majority of first-time users
- Facial flushing
- Spontaneous penile erection (described in a majority of male participants in early trials)
- Yawning and fatigue (likely CNS/MC4R mediated)
- Transient blood pressure elevation (confirmed in bremelanotide prescribing information; bremelanotide is contraindicated in cardiovascular disease partly for this reason)
- Darkening of pre-existing moles, with rare case reports of atypical nevus changes
Honest Head-to-Head Comparison Table
| Parameter | MT1 (Afamelanotide) | MT2 (Melanotan II) |
|---|---|---|
| Structure | 13-aa linear analog of alpha-MSH | 7-aa cyclic lactam peptide |
| Primary receptor | MC1R selective | MC1R, MC3R, MC4R, MC5R |
| FDA approval | Yes (EPP, 2019, 16 mg implant) | No |
| Tanning evidence quality | High (phase 3 RCT) | Moderate (small trials) |
| Erection effect | Not a recognized effect | Frequent in males; MC4R driven |
| Nausea burden | Low at clinical dose | High, especially on first dose |
| Cardiovascular concern | Not identified in EPP trials | Transient BP rise; caution in CVD |
| WADA status | Scrutinized outside medical use | Prohibited (peptide hormones category) |
| Legal availability | Prescription only (EPP indication) | Research compound; no approved use |
| Where MT1 wins | Safety data depth, regulatory clarity, site-reaction profile | N/A |
| Where MT2 wins (or is claimed to) | N/A | Faster cosmetic tanning (anecdotal), erection effect, lower MW and dose |
| Where both lose vs. alternatives | Neither beats a broad-spectrum SPF for preventing UV-induced skin damage. Neither is a substitute for PDE5 inhibitors in erectile dysfunction (better evidence, oral dosing, established cardiovascular safety profile in that context). | |
What Most Pages Get Wrong About MT1 vs MT2
The vast majority of comparison articles treat MT1 and MT2 as dose variants of the same drug, differing only in potency. That framing is pharmacologically wrong and practically dangerous. Here is what gets skipped:
1. MT2 is not a stronger MT1. It is a structurally different compound with a different receptor profile. "More tanning" does not capture the cardiovascular and CNS implications of MC4R agonism.
2. The mole risk is not theoretical. Several case reports in dermatology literature describe rapid or atypical changes in pre-existing nevi in individuals using melanotan II. The mechanism is straightforward: MC1R stimulation in melanocytes within nevi. This is not the same as causing melanoma, but it is a real monitoring concern that most vendor pages omit entirely.
3. Reconstituted peptide purity is not stable. Most comparison pages describe reconstitution as a simple step. They omit that reconstituted MT2 in bacteriostatic water begins degrading over days, that repeated warming to room temperature and re-refrigeration accelerates this, and that degraded product may contain diketopiperazine byproducts of uncertain bioactivity.
4. Community dosing is not clinical dosing. MT2 doses circulating in online forums (often 0.5 to 2 mg per injection) are substantially higher than the doses used in published human trials. The adverse event profile at forum doses has never been systematically characterized.
5. MT1 is not freely available. Pages sometimes imply MT1 is the "safe, approved" option that can be purchased alongside MT2. It cannot. Afamelanotide (Scenesse) is a prescription implant administered by a healthcare provider for a specific rare disease. Obtaining it outside that channel is obtaining an unapproved substance, whatever the labeling says.
Why the Storage and Stability Rules Exist
Both peptides degrade through two primary chemical pathways, and understanding these explains every storage instruction.
Hydrolysis: Peptide bonds are susceptible to water-mediated cleavage, especially at elevated temperature. This is why lyophilized (freeze-dried) powder is far more stable than liquid solution. Once water is introduced during reconstitution, the clock starts. At body temperature (37 degrees Celsius) degradation accelerates compared to refrigerator temperature (4 degrees Celsius). This is not unique to melanocortin peptides; it is true of all amide-bonded peptide therapeutics.
Methionine oxidation: MT1's native alpha-MSH parent contains a methionine at position 4 that is replaced by norleucine in afamelanotide precisely because methionine is oxidation-prone. MT2 does not contain methionine in its primary structure, but its phenylalanine and tryptophan residues can undergo UV-induced photooxidation. This is why both peptides should be stored in the dark and amber vials. UV exposure from a windowsill or lab bench over hours is sufficient to degrade a small peptide sample meaningfully.
Diketopiperazine (DKP) formation: Cyclic peptides like MT2 can undergo intramolecular rearrangement at the terminal residues to form diketopiperazines, especially in aqueous solution at room temperature. DKPs are biologically inactive fragments that accumulate in aged reconstituted vials. You will not see them visually, but they represent lost dose and unknown byproduct load.
Practical rule derivation: Store lyophilized powder below minus 20 degrees Celsius, away from light. Reconstitute with bacteriostatic water (0.9 percent benzyl alcohol as preservative). Refrigerate reconstituted solution at 2 to 8 degrees Celsius. Discard after 28 to 30 days. Never use a vial that has been left at room temperature for more than a few hours after reconstitution.
How to Read a COA and Judge a Peptide Product
A certificate of analysis (COA) is the minimum documentation required before considering any research peptide. Here is how to evaluate one:
| COA element | What to look for | Red flag |
|---|---|---|
| HPLC purity trace | Single dominant peak, purity above 98% | Purity stated as a number only, no chromatogram attached |
| Mass spectrometry | Confirmed MW: MT1 approximately 1646.9 Da; MT2 approximately 1024.2 Da | MW not reported or does not match expected value |
| Endotoxin testing | LAL assay result below 1 EU/mg for injectables | No endotoxin test for a product marketed as injectable |
| Lot number and date | Specific lot traceable to a test date | Generic or missing lot number |
| Testing lab identity | Named third-party laboratory | In-house testing only with no third-party verification |
Frequently Asked Questions
What is the core difference between MT1 and MT2 peptide?
MT1 (afamelanotide) is a 13-amino-acid linear analog of alpha-MSH that binds MC1R with high selectivity. MT2 (melanotan II) is a shorter, cyclic 7-amino-acid peptide that binds MC1R, MC3R, MC4R, and MC5R. The extra receptor activity of MT2 drives additional effects including spontaneous erections, appetite suppression, and a higher side-effect burden.
Which peptide produces a stronger tan, MT1 or MT2?
Head-to-head data are limited, but MT1 at the approved 16 mg subcutaneous implant dose produces clinically significant tanning in fair-skinned patients with erythropoietic protoporphyria. MT2 anecdotally produces faster initial darkening, largely because its broader receptor binding may amplify melanocyte stimulation, but no randomized trial has directly compared the two in healthy volunteers.
Does MT2 cause erections and does MT1?
MT2 frequently causes spontaneous erections through MC4R agonism in the hypothalamus; this was reported in a majority of male participants in the early Wessells et al. trial. MT1 has very low MC4R affinity and erections are not a recognized effect at clinical doses. Bremelanotide (PT-141), an MT2 metabolite, is FDA-approved for hypoactive sexual desire disorder, confirming this pathway is real.
Is MT1 peptide FDA approved?
Yes. Afamelanotide (Scenesse) received FDA approval in October 2019 for prevention of phototoxicity in adults with erythropoietic protoporphyria. It is delivered as a 16 mg biodegradable subcutaneous implant. MT2 has no FDA approval for any indication.
What are the most common side effects of MT2 versus MT1?
MT2 side effects include nausea, flushing, spontaneous erections, yawning, and fatigue, often within 30 to 60 minutes of injection. MT1 (afamelanotide) in phase 3 trials showed implant-site reactions and mild nausea as the most frequent adverse events, with a markedly lower incidence of systemic effects compared to MT2.
What receptors do MT1 and MT2 bind?
MT1 binds primarily MC1R (Ki in the low nanomolar range) with minimal activity at MC3R and MC4R. MT2 binds MC1R, MC3R, MC4R, and MC5R. MC4R binding explains erections and appetite suppression; MC3R binding relates to energy homeostasis; MC5R binding may affect exocrine secretion.
Can MT2 be used for erectile dysfunction?
MT2 and its metabolite bremelanotide have been studied for erectile function. Bremelanotide (PT-141) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. For male erectile dysfunction, bremelanotide showed effect in early trials, but MT2 itself is not approved, not standardized in dose, and carries cardiovascular and nausea risks not shared with PDE5 inhibitors.
How should MT1 and MT2 peptides be stored?
Both peptides degrade via hydrolysis at elevated temperature and through oxidation. Lyophilized powder is stable for months at minus 20 degrees Celsius in the dark. Once reconstituted in bacteriostatic water, refrigerate at 2 to 8 degrees Celsius and use within 28 to 30 days. UV light and repeated freeze-thaw cycles accelerate degradation.
How do MT1 and MT2 compare to self-tanning products or UV exposure?
MT1 produces genuine eumelanin synthesis, offering some photoprotective benefit. DHA-based self-tanners stain the stratum corneum with no melanin production and no UV protection. Controlled UV tanning carries well-documented skin cancer risk. MT1 is the only option that increases melanin without UV, but it requires injection and medical supervision.
What does a degraded or low-purity MT1 or MT2 vial look like?
Lyophilized peptide should be a white to off-white cake or powder. Yellow or brown discoloration suggests oxidation or impurities. After reconstitution, the solution should be clear and colorless. Cloudiness, visible particles, or a pink tinge all indicate degradation or contamination. Never inject a discolored or cloudy solution.
Is MT2 banned in sports?
WADA includes melanocortin peptides, including MT2, on the Prohibited List under peptide hormones and related substances. MT1 (afamelanotide) as a prescription drug for EPP is in a different regulatory category, but athletes using it cosmetically outside its medical indication would face scrutiny under spirit-of-sport rules.
What purity should I look for on a COA for MT1 or MT2?
For research-grade peptides, HPLC purity above 98 percent is the standard benchmark. Mass spectrometry confirmation of molecular weight (afamelanotide approximately 1646.9 Da, melanotan II approximately 1024.2 Da) verifies identity. A COA without an HPLC trace is insufficient. Endotoxin testing (LAL assay) should also be present for any injectable compound.
Sources
- Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 2015;373(1):48-59.
- FDA Center for Drug Evaluation and Research. Scenesse (afamelanotide) Prescribing Information. NDA 210797. Approved October 8, 2019.
- FDA Center for Drug Evaluation and Research. Vyleesi (bremelanotide) Prescribing Information. NDA 210557. Approved June 21, 2019.
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. 1998;160(2):389-393.
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.
- Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 2000;72(4):526-532.
- Mountjoy KG. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochemical Journal. 2010;428(3):305-324.
- World Anti-Doping Agency. Prohibited List 2024. Section 2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.
- Bremelanotide (PT-141) prescribing information. AMAG Pharmaceuticals. 2019. [Includes transient blood pressure elevation data from phase 3 RECONNECT trials.]
- Ugajin T, Miyamoto T, Nishida K, et al. Rapid darkening of a melanocytic nevus during melanotan II injections: a case report. Dermatology Reports. [Case report literature; cited for mole-change signal, not causality proof.]
- Eves PC, MacNeil S, Haycock JW. Alpha-melanocyte stimulating hormone, inflammation and human melanoma. Peptides. 2006;27(2):444-452.